Simulations Plus, Inc.  

(Public, NASDAQ:SLP)   Watch this stock  
Find more results for SLP
11.70
0.00 (0.00%)
Apr 28 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 11.70 - 11.85
52 week 6.74 - 12.25
Open 11.78
Vol / Avg. 15,711.00/45,575.00
Mkt cap 201.72M
P/E 38.55
Div/yield 0.05/1.71
EPS 0.30
Shares 17.24M
Beta -0.43
Inst. own 27%
Jul 12, 2017
Q3 2017 Simulations Plus Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
May 17, 2017
Simulations Plus Inc at Needham Emerging Technology Conference - 12:50PM EDT - Add to calendar
Apr 10, 2017
Q2 2017 Simulations Plus Inc Earnings Call - Webcast
Mar 13, 2017
Q2 2017 Simulations Plus Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Feb '17) 2016
Net profit margin 20.96% 24.79%
Operating margin 31.46% 36.21%
EBITD margin - 37.93%
Return on average assets 16.75% 17.95%
Return on average equity 20.31% 23.42%
Employees 60 -
CDP Score - -

Address

42505 10th St W
LANCASTER, CA 93534-7059
United States - Map
+1-661-7237723 (Phone)
+1-661-7235524 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Simulations Plus, Inc. (Simulations Plus) develops and produces software for use in pharmaceutical research and for education, and provides consulting and contract research services to the pharmaceutical industry. The Company offers five software products for pharmaceutical research. ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) Predictor is a computer program that takes molecular structures as inputs and predicts over 140 different properties for them at the rate of about 200,000 compounds per hour. MedChem Designer includes a small set of ADMET Predictor property predictions, allowing the chemist to modify molecular structures. MedChem Studio is a tool for medicinal and computational chemists for both data mining and for designing new drug-like molecules. DDDPlus simulates in-vitro laboratory experiments used to measure the rate of dissolution of the drug. GastroPlus simulates the absorption, pharmacokinetics, and pharmacodynamics of drugs.

Officers and directors

Walter S. Woltosz Chairman of the Board, Chief Executive Officer
Age: 71
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Thaddeus Henry Grasela Jr President, Director
Age: 62
Bio & Compensation  - Reuters
John R. Kneisel CPA Chief Financial Officer
Age: 58
Bio & Compensation  - Reuters
John A. DiBella II Vice President - Sales & Marketing
Age: 36
Bio & Compensation  - Reuters
John Kenneth Paglia Independent Director
Age: 49
Bio & Compensation  - Reuters
David L. Ralph Independent Director
Age: 69
Bio & Compensation  - Reuters